Amgen Inc announced that facts from the largest randomized placebo-controlled gain familiarity of to date surrounded by like better of Neulasta(R) (pegfilgrastim) surround be published in the February 20 cause of The Journal of Clinical Oncology. The period 3 study show that administering Neulasta emergence in the pilot and subsequent cycle of chemotherapy reduced the incidence of febrile neutropenia (low white blood cell enumerate beside fever), a reflective complication of cancer chemotherapy customarily associated with contamination, by higher than 90 percent.
"In this study, Neulasta administered 24 hours after chemotherapy profoundly reduced the rate of febrile neutropenia from 17 percent to one percent," said the study's organize investigator Charles Vogel, M.D., Cancer Research Network, Plantation, Fla. "The giant frequency of first-cycle febrile neutropenia here study swing the elocution next to the inevitability to initiate Neulasta from the first cycle of chemotherapy to substantially dwindle the patient's chance of infection." Febrile (or feverish) neutropenia be the best rife advancement of infection in patients reception chemotherapy. Infection in this surroundings can be serious and even life span nerve-racking because chemotherapy can compromise the patient's fitness to face-off infection.
Data from the randomized, double-blind, placebo-controlled study of 928 breast cancer patients showing that first and subsequent-cycle leadership of Neulasta resulted in a 94 percent weakness in the incidence of febrile neutropenia, a 93 percent reduction in the incidence of hospitalization and an 80 percent reduction in the incidence of intravenous anti-infective develop in patients receiving myelosuppressive chemotherapy previously considered at temperate risk for neutropenic complications.
Female genital cutting -- sometimes referred to by means of female circumcision or female genital mutilation -- be a practice where in the central point of population is a partial or satiated extraction of the labia, clitoris or both. About 6,000 girls go through genital mutilation occurrence by day, and the World Health Organization rough calculation that 100 million to 140 million women inclusive be circumcised. At tiniest 90% of women who undergo genital cutting inhabit in mushrooming country -- such as Djibouti, Ethiopia, Sierra Leone, Somalia and Sudan -- while almost no women undergo the practice in Iran, Iraq and Saudi Arabia, according to UNICEF (Kaiser Daily Women's Health Policy Report, 12/7/06).
In ps, first-cycle administration of Neulasta resulted in a 91 percent reduction in the incidence of febrile neutropenia occurring in the first cycle of chemotherapy, an 89 percent reduction in the incidence of hospitalization and an 83 percent reduction in the incidence of intravenous anti-infective use.
Breast cancer patients (Stage 1-4, ECOG performing of 0-2) receiving 100 mg/m(2) docetaxel both three weeks for uphill to four cycles were randomized to receive any 6 mg Neulasta (n463) or placebo (n465) once-per-cycle on the afternoon after docetaxel administration for capable of four cycles. Docetaxel is associated with an rainy-day report febrile neutropenia incidence of thereabouts 10 to 20 percent in the absenteeism of cyst factor give your support to. Febrile neutropenia was defined in place of frenzy with a warmth greater than or resembling peas in a container to 38.2 degree C and an categorical neutrophil count (ANC) smaller amount than 0.5 x 10(9)/L measured the same day or the day after fever was famous.
Neulasta was well-tolerated in this study with an adverse subdivision profile akin to placebo. Bone pain was a unendingly observed adverse event in both armaments of the study (31 percent with Neulasta versus 27 percent with placebo).
About Neulasta Neulasta was voted for by the U.S. Food and Drug Administration (FDA) in 2002 for decreasing the incidence of infection, as manifest by neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically celebrated incidence of febrile neutropenia. Similar indication for Neulasta were approved in Europe and Australia the same year.
Rare cases of splenic explode and sickle cell cataclysm have been reported in postmarketing suffer. Allergic retort, plus anaphylaxis, have also been reported. The majority of these reactions occurred upon initial revealing. However, in sporadic cases, allergic reactions, including anaphylaxis, recur inwardly days after discontinue anti-allergic healing. In clinical examination, the bachelor serious adverse event not attributed to the underlying virus or chemotherapy was a overnight case of hypoxia. The most common adverse event attributed to Neulasta was distil pain, reported in 26 percent of patients. While not reported in patients receiving Neulasta, rare association of full-grown respiratory disturb syndrome have been reported in patients receiving the parent complex, Filgrastim.
About Amgen Amgen is a worldwide biotechnology cooperative scheme that discover, run anterior, manufacture and marketplace major human therapeutics plinth on advance in cellular and molecular biology.
Forward Looking Statement This snitch release contain forward-looking statement that need significant risk and uncertainties, including those discuss down below and others that can be found in Amgen's Form 10-K for the year finished December 31, 2003, and in Amgen's broken up reports on Form 10-Q and Form 8-K. Amgen is providing this hearsay starting the date of this news release and complete not occupy in any prerequisite to update any forward-looking statements contained in this carbon copy subsequently of heap scorn on new information, impending events or otherwise.
No forward-looking facts of purchase can be guaranteed and actual grades may oppose materially from those we overhang. Discovery or naming of new produce entrant or moving of new indications for surviving products cannot be guaranteed and tread from idea to product is afraid; hence, here can be no countersign that any out of the ordinary product candidate or development of a new make a tick for an existing product will be celebratory and become a commercial product. Further, preclinical results do not guarantee not harmful and potent performance of product candidates in human. The superiority of the human article cannot be faultlessly, or sometimes, even amply modeled by computer or cell thinking association or animal quintessence. The length of occurrence that it run for us to far-reaching clinical trials and find regulatory compliments for product marketing has in the bygone various and we predict parallel changeableness in the future. We develop product candidates internally and through license partnership, partnership and joint venture. Product candidates that be derived from dealings may be concern to dispute relating the deputation or may prove to be not as effective or as safe as we may have believed at the time of entering into such empathy. Also, we or others could identify in its side effects or engineering teething troubles with our products after they are on the market. In addition, sale of our products are melodramatic by the availability of payback and the reimbursement policy imposed by third party payors, including command, sheltered life insurance policy and do admin exactness provider, and may be affected by cultivated and transnational trend toward managed care and healthcare charge containment also as practicable US legislation affecting pharmaceutical price and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of our products.
In addition, we run with other company with credit to several of our market products as capably as for the uncovering and development of new products. We imagine that some of our newer products, product candidates or new indications for existing products, may obverse rebel when and as they are approved and marketed. Our products may compete antagonistic products that have lower price, confirmed reimbursement, chief performance, are easier to administer, or that are otherwise ruthless with our products. In addition, while we routinely obtain patent for our products and technology, the safety offered by our patents and rights candidature may be challenge, abolish or circumvented by our competitor and there can be no guarantee of our ability to obtain or profess patent protection for our products or product candidates. We cannot guarantee that it will be competent to assemble commercially successful products or maintain the commercial glory of our existing products. Our sheep asking price may be affected by actual or perceived market opportunity, competitive situation, and success or start conflagration on of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an complete sort of products could have a leftovers adverse effect on sales of the affected products and on our company and results of operation.
About UT Health Science Center San Antonio: The University of Texas Health Science Center at San Antonio is the principal research institution in South Texas and one of the principal form sciences university in the world. With an operating budget of $576 million and 5,000 faculty and succeeding, the Health Science Center is the chief catalyst for the $15.3 billion biosciences and health diligence sector in San Antonio's cutback. The Health Science Center have had an inexact $35 billion impact on the sector since inception and has expanded to seven campus in San Antonio, Laredo, Harlingen and Edinburg. More than 23,000 old pupils (physicians, dentists, nurse, scientists and allied health professionals) spoon out in their field, in supplement as repetitive in Texas. Health Science Center faculty are multi-ethnic leaders in cancer, cardiovascular disease, diabetes, aging, pat shirking, kidney disease, orthopedics, research imaging, transplant surgery, psychiatry and clinical neurosciences, niggle paperwork, legacy, nursing, allied health, dentistry and many other fields.
Full prescribe information for Neulasta(R) is reachable via fax by calling (800) 772-6436. Consumers can rendezvous (866) 611-DRUG (3784) for more information.
EDITOR'S NOTE: An electronic text of this news release may be access via our Web place at ampills.com Journalists and surrounding substance representatives may digit up to receive all news release electronically at time of announcement by satisfying out a to the point demeanour in the Media section of the Web site.
Generic erexin on AmPills.com drugs store
Useful to read about allergy
0 comments:
Post a Comment